Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

145.98 +0.78 (+0.54%)
Streaming Delayed Price Updated: 2:01 PM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
40 Consistent Attractively Valued Dividend Growth Stocks
hese companies have consistent long-term operating history and solid prospects for future growth. 
Via Talk Markets
AbbVie Submits Upadacitinib Applications In US, Europe For Ulcerative Colitis
AbbVie Inc (NYSE: ABBV) has submitted applications seeking approval for upadacitinib (15 mg and 30 mg (maintenance dose) and 45 mg (induction dose)) for active... 
Via Benzinga
25 Best & 10 Cheapest Dividend Aristocrats
These are blue-chip dividend-paying stocks that have increased their dividend for at least 25 consecutive years or longer. 
Via Talk Markets
Is AbbVie's 4.9% Dividend Yield Safe?
Should investors pick up the stock after its recent sell-off? 
Via The Motley Fool
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal
Gene therapy is set to become one of the most vital spaces with high prospects in the biotech sector. 
Via Talk Markets
Regenxbio Stock Catapults To 7-Month High On AbbVie's $1.75 Billion Bet On Gene Therapy
Regenxbio stock rocketed Monday after the company announced an AbbVie eye-disease deal. At one point, RGNX stock hit a seven-month high. 
Via Investor's Business Daily
Why Regenxbio Stock Is Way Up Today
American biopharmaceutical giant AbbVie wants access to Regenexbio's gene therapy for macular degeneration. 
Via The Motley Fool
Why Regenxbio Shares Are Trading Higher Today
Regenxbio Inc (NASDAQ: RGNX) is trading significantly higher Monday after the company, and AbbVie Inc (NYSE: ABBV), announced an eye care collaboration. The companies will develop... 
Via Benzinga
AbbVie, RegenXBio Ink $1.75B Retinal Gene Therapy Collaboration
AbbVie Inc (NYSE: ABBV) and Regenxbio Inc (NASDAQ: RGNX) have partnered to develop and commercialize RGX-314, potential one-time gene therapy for wet age... 
Via Benzinga
Why Shares of Johnson & Johnson Are Down 2% Today
The list of ideas is only the start of the legislative process. 
Via The Motley Fool
Could This Label Expansion Be a Blockbuster for AbbVie's Shareholders?
The EC's approval of Rinvoq for moderate to severe eczema is another step in the right direction for the company. 
Via The Motley Fool
The Latest Barron's Picks And Pans Include General Electric, Netflix, Reddit And More
This weekend's Barron's reveals what market strategists recommend for a stock market that likely will struggle this fall. Other featured articles discuss biotech stocks... 
Via Benzinga
Dow Up Triple Digits, Poised to Snap Three-Day Skid
The Dow Jones Industrial Index is staging a bounce off yesterday's lukewarm trading, last seen up 150 points, and set to snap a three-day losing streak. 
Via Talk Markets
Topics Stocks
Exposures US Equities
FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know
The FDA wrapped up its long-awaited review of Pfizer Inc's (NYSE: PFE) large, randomized trial evaluating the safety of JAK inhibitors Xeljanz and Xeljanz XR... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV... 
Via Benzinga
Exposures COVID-19 Product Safety
3 Biotech Stocks That Are Too Cheap to Ignore
You'll definitely want to check out these biotech bargains. 
Via The Motley Fool
'Fast Money Halftime Report' Picks For AbbVie, UnitedHealth And More
On CNBC's "Fast Money Halftime Report," Joe Terranova said he will probably sell half of his position in AbbVie Inc (NYSE: ABBV) after the stock declined on FDA... 
Via Benzinga
ABBV Stock: The FDA Blow That Just Sent AbbVie Tumbling on Wednesday
Here's the big FDA-related news today that's sparking a sharp selloff of pharmaceutical giant AbbVie and ABBV stock. 
Via InvestorPlace
Exposures Product Safety
Why AbbVie Is Down More Than 7% Today
The Food and Drug Administration is drawing reasonable conclusions, but not necessarily conclusions that matter much to consumers. 
Via The Motley Fool
Exposures Product Safety
Why AbbVie's Stock Is Trading Lower Today
AbbVie Inc. (NYSE: ABBV) shares are trading lower as traders circulate an earlier updated FDA warning on the company's Xeljanz. "Based on a completed U.S. FDA review of a... 
Via Benzinga
Exposures Product Safety
AbbVie Stock: Why A New FDA Order Hit It Harder Than Rivals Pfizer, Lilly
AbbVie stock collapsed Wednesday after the FDA said it would have to add a warning to the label for arthritis drug Rinvoq. 
Via Investor's Business Daily
Exposures Product Safety
3 Top Warren Buffett Stocks to Buy in September
They've lagged behind the S&P 500 so far this year, but all three should be great long-term winners. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New... 
Via Benzinga
If You're Retired, Consider Buying These 2 Stocks
Reliable cash flows and a history of payout hikes should hold retirees in good stead. 
Via The Motley Fool
Is Warren Buffett Making A Mistake By Selling These Stocks?
Warren Buffett is a hero of mine. However, Buffett is human like the rest of us, and he makes mistakes. Well, he might be making a mistake right now. 
Via Talk Markets
Could These Clinical Results Mean Profit for AbbVie Shareholders?
The pharma stock announced strong phase 3 results for atogepant in the preventive treatment of episodic migraine. 
Via The Motley Fool
This Warren Buffett Dividend Stock Is Still Dirt Cheap
The Oracle of Omaha has already made a great return from his investment in this big pharma stock. 
Via The Motley Fool
5 Best Dividend Stocks To Buy Now
There's no better time than now to invest in dividend stocks. And some of the best dividend stocks that beat the S&P 500's average yield of 2% can be found in the healthcare sector. 
Via Talk Markets
Topics Stocks
Exposures US Equities
The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures COVID-19
3 Pharma Stocks to Buy With Juicy Dividends
And there's more than just dividends to like with these big pharma stocks. 
Via The Motley Fool
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.